natgillin/translations-raw huggingface dataset:
Administration of a single dose of EVOTAZ with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 42% increase in atazanavir Cmax, a 28% increase in atazanavir AUC, a 31% increase in cobicistat Cmax, and a 24% increase in cobicistat AUC relative to the fasting state.
Primjena jedne doze lijeka EVOTAZ uz lagan obrok (336 kcal, 5,1 g masnoća, 9,3 g proteina) povećala je Cmax atazanavira za 42%, AUC atazanavira za 28%, Cmax kobicistata za 31% i AUC kobicistata za 24% u odnosu na primjenu natašte.
Buprenorphine AUC: ↑35% Buprenorphine Cmax: ↑66% Buprenorphine Cmin: ↑12%
Buprenorfin AUC: ↑35% Buprenorfin Cmax: ↑66% Buprenorfin Cmin: ↑12%
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics) St John's wort (Hypericum perforatum) (herbal product) rifampicin (antimycobacterial)
Istodobna primjena sa sljedećim lijekovima, koji su snažni induktori izooblika CYP3A4 citokroma P450, zbog mogućeg gubitka terapijskog učinka (vidjeti dio 4.5): karbamazepin, fenobarbital, fenitoin (antiepileptici) gospina trava (Hypericum perforatum) (biljni pripravak). rifampicin (antimikobakterijski lijek)
Co-administration of EVOTAZ with medicinal products that are strong inducers of CYP3A (such as carbamazepine, phenobarbital, phenytoin, rifampicin, and St. John's wort [Hypericum perforatum]) may result in decreased plasma concentrations of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir (see section 4.3 and Table 1).
Istodobna primjena lijeka EVOTAZ i lijekova koji su jaki induktori CYP3A (kao što su karbamazepin, fenobarbital, fenitoin, rifampicin i gospina trava [Hypericum perforatum]) može za posljedicu imati smanjene plazmatske koncentracije atazanavira i/ili kobicistata, što dovodi do gubitka terapijskog učinka i mogućeg razvoja rezistencije na atazanavir (vidjeti dio 4.3 i Tablicu 1).
Co-administration with EVOTAZ may cause a large increase in the concentration of these benzodiazepines.
Istodobna primjena s lijekom EVOTAZ može jako povisiti koncentracije tih benzodiazepina.
Co-administration of EVOTAZ with these medicinal products is expected to substantially increase their concentrations and may result in PDE5-associated adverse reactions such as hypotension, visual changes and priapism (see section 4.5).
Pri istodobnoj primjeni lijeka EVOTAZ i tih lijekova očekuje se znatno povećanje njihove koncentracije, što može rezultirati nuspojavama povezanima s PDE5, kao što su hipotenzija, poremećaji vida i prijapizam (vidjeti dio 4.5).
Among naïve patients treated with atazanavir 300 mg once daily with 100 mg ritonavir once daily for a median duration of 96 weeks, 48% had Grade 3-4 total bilirubin elevations (see section 4.4).
Među bolesnicima koji prethodno nisu bili liječeni i primali su atazanavir u dozi od 300 mg jedanput na dan sa 100 mg ritonavira jedanput na dan tijekom medijana od 96 tjedana, njih 48% imalo je povišenje ukupnog bilirubina 3.-4. stupnja (vidjeti dio 4.4).
EVOTAZ must not be co-administered with colchicine to patients with renal or hepatic impairment.
EVOTAZ se ne smije primjenjivati istodobno s kolhicinom u bolesnika s oštećenjem bubrežne ili jetrene funkcije.
In female mice, atazanavir exposure at a dose that produced single-cell necrosis was 12 times the exposure in humans given 400 mg once daily.
U ženki miša, izloženost atazanaviru u dozi koja je izazvala nekrozu pojedinačnih stanica bila je 12 puta veća od izloženosti u ljudi koji su primali dozu od 400 mg jedanput na dan.
The use of EVOTAZ is contraindicated in patients with moderate to severe hepatic impairment.
Primjena lijeka EVOTAZ kontraindicirana je u bolesnika s umjerenim do teškim oštećenjem jetrene funkcije.
The mechanism of interaction is inhibition of metabolism by atazanavir.
Mehanizam interakcije je inhibicija metabolizma koju uzrokuje atazanavir.
No meaningful differences in cobicistat pharmacokinetics were observed between subjects with severe renal impairment and healthy subjects, consistent with low renal clearance of cobicistat.
Nisu opažene značajne razlike u farmakokinetici kobicistata između ispitanika s teškim oštećenjem funkcije bubrega i zdravih ispitanika, što je u skladu s niskim stupnjem bubrežnog klirensa kobicistata.
No dose adjustment of cobicistat is required in patients with mild or moderate hepatic impairment.
Nije potrebno prilagođavati dozu kobicistata u bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije.
The mechanism of interaction is a reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.
Mehanizam interakcije je smanjenje topljivosti atazanavira uz povećanje pH povezano s prisutnošću antacida u puferiranim tabletama didanozina.
EVOTAZ must not be used in patients with moderate to severe hepatic impairment (see section 4.3).
EVOTAZ se ne smije primjenjivati u bolesnika s umjerenim do teškim oštećenjem jetrene funkcije (vidjeti dio 4.3).
Combinations of EVOTAZ and indinavir have not been studied and co-administration of these medicinal products is not recommended (see section 4.5).
Kombinacije lijeka EVOTAZ i indinavira nisu ispitivane pa se njihova istodobna primjena ne preporučuje (vidjeti dio 4.5).
The effects of hepatic impairment on the pharmacokinetics of atazanavir given with cobicistat have not been studied.
Učinci oštećenja funkcije jetre na farmakokinetiku atazanavira primijenjenog s kobicistatom nisu se ispitivali.
Unlike ritonavir, cobicistat is not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1.
Za razliku od ritonavira, kobicistat ne inducira CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ni UGT1A1.
ANTIMYCOBACTERIALS
ANTIMIKOBAKTERIJSKI
Serious skin rash, including Stevens-Johnson syndrome, may develop in patients taking EVOTAZ.
U bolesnika koji su uzimaju EVOTAZ može se razviti ozbiljan kožni osip, uključujući StevensJohnsonov sindrom.
Concomitant use contraindicated
Istodobna primjena koja je kontraindicirana
Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2 and 5.2).
Atazanavir se prvenstveno metabolizira u jetri, pa su u bolesnika s oštećenjem jetrene funkcije bile opažene povišene koncentracije atazanavira u plazmi (vidjeti dijelove 4.2 i 5.2).
The mechanism of interaction between efavirenz and atazanavir, or efavirenz and cobicistat is CYP3A4 induction by efavirenz.
Mehanizam interakcije između efavirenza i atazanavira ili efavirenza i kobicistata je indukcija CYP3A4 koju uzrokuje efavirenz.
Contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3)
Kontraindicirano zbog mogućeg povećanog rizika povišenja ALT-a zbog značajnog povišenja koncentracije glekaprevira i pibrentasvira u plazmi (vidjeti dio
The median baseline CD4+ cell count was 352 cells/mm3 (range: 1-1455) and 16.9% had CD4+ cell counts ≤200 cells/mm3.
Medijan dobi ispitanika iznosio je 36 godina (raspon: Medijan početne plazmatske vrijednosti HIV-1 RNK bio je 4,81 log10 kopija/ml (raspon: The median baseline CD4+ cell count was 352 cells/mm3 (range: 1-1455) and 16.9% had CD4+ cell counts ≤200 cells/mm3.
How to store EVOTAZ
Kako čuvati EVOTAZ
The mechanism of interaction is CYP3A induction by the antiepileptic.
Mehanizam interakcije je indukcija CYP3A koju uzrokuje antiepileptik.
Co-administration of nevirapine and cobicistat is expected to decrease cobicistat plasma concentrations while nevirapine plasma concentrations may be increased.
Očekuje se da će istodobna primjena nevirapina i kobicistata sniziti plazmatske koncentracije kobicistata, dok bi plazmatske koncentracije nevirapina mogle porasti.
Co-administration of EVOTAZ with medicinal products containing ritonavir or cobicistat, which are strong inhibitors of CYP3A, may result in additional boosting and increased plasma concentration of atazanavir.
Istodobna primjena lijeka EVOTAZ i lijekova koji sadrže ritonavir ili kobicistat, koji su snažni inhibitori CYP3A, može dodatno pojačati učinak i povisiti plazmatske koncentracije atazanavira.
The antiretroviral effect of EVOTAZ is due to the atazanavir component.
Antiretrovirusni učinak lijeka EVOTAZ posljedica je djelovanja sastavnice atazanavira.
What EVOTAZ looks like and contents of the pack EVOTAZ tablets are pink, oval, biconvex, film coated tablet of approximate dimensions of 19 mm x 10.4 mm, debossed on one side with "3641" and plain-faced on the other side of the tablet.
EVOTAZ tablete su ružičaste, ovalne, bikonveksne, filmom obložene tablete dimenzija približno 19 mm x 10,4 mm, s utisnutom oznakom "3641" na jednoj strani i bez oznake na drugoj strani tablete.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co-administration with EVOTAZ may result in increased concentrations.
Metabolizam simvastatina i lovastatina jako ovisi o CYP3A4 pa istodobna primjena s lijekom EVOTAZ može povisiti njihove koncentracije.
In study GS-US-216-0114, the mean increase from baseline in CD4+ cell count at weeks 48 and 144 were 213 and 310 cells/mm3 in patients receiving atazanavir boosted with cobicistat and 219 and 332 cells/mm3 in patients receiving atazanavir boosted with ritonavir, respectively.
U ispitivanju GS-US-216-0114, srednje povećanje broja CD4+ stanica od početne vrijednosti u 48 odnosno 144. tjednu iznosilo je 213 odnosno 310 stanica/mm3 u bolesnika liječenih atazanavirom pojačanim kobicistatom te 219 odnosno 332 stanice/mm3 u bolesnika liječenih atazanavirom pojačanim ritonavirom.
No dosage adjustment is necessary if methadone is co-administered with EVOTAZ.
Nije potrebno prilagođavati dozu kada se metadon primjenjuje istodobno s lijekom EVOTAZ.
Co-administration of EVOTAZ and rifabutin is not recommended.
Ne preporučuje se istodobna primjena lijeka EVOTAZ i rifabutina.
f Plus background regimen of emtricitabine 200 mg and tenofovir DF 300 mg fixed-dose combination.
f Plus osnovni režim liječenja fiksnom kombinacijom emtricitabina u dozi od 200 mg i tenofovira DFu dozi od
Cobicistat is a weak CYP2D6 inhibitor and is metabolised to a minor extent by CYP2D6.
Kobicistat je slab inhibitor CYP2D6 i u manjoj se mjeri metabolizira putem CYP2D6.
Alternative antiretroviral therapy to EVOTAZ may be considered if jaundice or scleral icterus is unacceptable to a patient.
Može se razmotriti primjena neke druge antiretrovirusne terapije umjesto lijeka EVOTAZ ako su žutilo kože ili bjeloočnica bolesniku neprihvatljivi.
If drospirenone/ethinyloestradiol is coadministered with atazanavir/cobicistat, clinical monitoring is recommended due to the potential for hyperkalemia.
Ako se drospirenon/etinilestradiol primjenjuje istodobno s atazanavir/kobicistatom preporučuje se kliničko praćenje zbog moguće hiperkalemije.
There are no pharmacokinetic data regarding the use of EVOTAZ in patients with hepatic impairment.
Nema farmakokinetičkih podataka o primjeni lijeka EVOTAZ u bolesnika s oštećenjem jetrene funkcije.
No data are available on the pharmacokinetics of atazanavir and cobicistat in combination in paediatric patients.
Nema dostupnih podataka o farmakokinetici kombinacije atazanavira i kobicistata u pedijatrijskih bolesnika.
It is unknown if cobicistat/metabolites are excreted in human milk.
Nije poznato izlučuju li se kobicistat/njegovi metaboliti u majčino mlijeko.
Higher concentrations could potentiate tenofovir-associated adverse reactions, including renal disorders.
Povišene koncentracije mogu potencirati nuspojave povezane s primjenom tenofovira, uključujući bubrežne poremećaje.
Co-administration with EVOTAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-associated adverse events, including hypotension, visual changes, and priapism.
Istodobna primjena s lijekom EVOTAZ može povisiti koncentracije inhibitora PDE5 i pojačati nuspojave povezane s PDE5, uključujući hipotenziju, poremećaje vida i prijapizam.
Animal studies do not indicate direct or indirect harmful effects of cobicistat with respect to reproductive toxicity (see section 5.3).
Ispitivanja na životinjama ne ukazuju ni na kakve izravne ni neizravne štetne učinke kobicistata na reprodukciju (vidjeti dio 5.3).
Tablet core - microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), sodium starch glycolate, crospovidone (E1202), stearic acid (E570), magnesium stearate (E470b), hydroxypropyl cellulose (E463), silicon dioxide (E551) Film-coating - hypromellose (hydroxypropyl methyl cellulose, E464), titanium dioxide (E171), talc (E553b), triacetin (E1518), red iron oxide (E172)
Jezgra tableta - mikrokristalična celuloza (E460(i)), umrežena karmelozanatrij (E468), natrijev škroboglikolat, krospovidon (E1202), stearatna kiselina (E570), magnezijev stearat (E470b), hidroksipropilceluloza (E463), silicijev dioksid (E551) Film ovojnica - hipromeloza (hidroksipropilmetilceluloza, E464), titanijev dioksid (E171), talk (E553b), triacetin (E1518), crveni željezov oksid (E172)
Co-administration of EVOTAZ with medicinal products that are moderate to weak inducers of CYP3A may result in decreased plasma concentration of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir.
Istodobna primjena lijeka EVOTAZ i lijekova koji su umjereni do slabi induktori CYP3A može dovesti do smanjenja plazmatskih koncentracija atazanavira i/ili kobicistata, što dovodi do gubitka terapijskog učinka i mogućeg razvoja rezistencije na atazanavir.
When compared to their single-agent profiles all findings could be attributed to either atazanavir or cobicistat.
U usporedbi s profilima tih dvaju lijekova primijenjenih samostalno, svi su se nalazi mogli pripisati atazanaviru ili kobicistatu.
Clinically significant interactions between EVOTAZ and substrates of CYP1A2, CYP2B6, CYP2C9 or CYP2C19 are not expected.
Ne očekuju se klinički značajne interakcije između lijeka EVOTAZ i supstrata za CYP1A2, CYP2B6, CYP2C9 ili CYP2C19.
Reversible elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT) have occurred in patients receiving atazanavir (see section 4.8).
U bolesnika koji su primali atazanavir nastupilo je reverzibilno povišenje razine indirektnog (nekonjugiranog) bilirubina povezano s inhibicijom UDP-glukuronozil transferaze (UGT) (vidjeti dio 4.8).
Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function.
Pokazalo se da kobicistat smanjuje procijenjeni klirens kreatinina zbog inhibicije tubularne sekrecije kreatinina, ali zapravo ne utječe na funkciju bubrežnih glomerula.
No human data on the effect of cobicistat on fertility are available.
Nisu dostupni podaci o utjecaju kobicistata na plodnost ljudi.
HIV-1 RNA <50 copies/ml
Virološki uspjeh HIV-1 RNK < 50 kopija/ml Razlika između liječenja
Concentrations of atazanavir given with cobicistat are expected to be increased in patients with impaired hepatic function (see sections 4.2 and 4.4).
Očekuje se da će koncentracije atazanavira primijenjenog s kobicistatom biti povišene u bolesnika s oštećenom funkcijom jetre (vidjeti dijelove 4.2 i 4.4).
EVOTAZ is expected to increase rilpivirine plasma concentrations.
Očekuje se da će EVOTAZ povisiti plazmatske koncentracije rilpivirina.
Concomitant use of EVOTAZ and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.
Istodobnom primjenom EVOTAZA i kortikosteroida koji se metaboliziraju putem CYP3A (npr.flutikaznpropionata ili drugih inhalacijskih ili nazalnih kortikosteroida), ukljućujući Cushingov sindrom i adrenalnu supresiju.
Because atazanavir is a component of EVOTAZ, the combination of EVOTAZ with atorvastatin is not recommended (see section 4.5).
Budući da je atazanavir sastavnica lijeka EVOTAZ, ne preporučuje se kombinacija lijeka EVOTAZ i atorvastatina (vidjeti dio 4.5).
Co-administration of medicinal products that are substrates of CYP3A and have narrow therapeutic indeces and for which elevated plasma concentrations are associated with serious and/or life-threatening events are contraindicated with EVOTAZ.
Kontraindicirana je istodobna primjena lijeka EVOTAZ i lijekova koji su supstrati za CYP3A i imaju uzak terapijski indeks i čije se povišene plazmatske koncentracije povezuju s ozbiljnim i/ili po život opasnim događajima.
Some patients have reported dizziness when taking atazanavir or cobicistat, active substances of EVOTAZ.
Neki su bolesnici prijavili omaglicu tijekom primjene atazanavira ili kobicistata, djelatnih tvari lijeka EVOTAZ.
Famotidine 20 mg twice daily (atazanavir 300 mg/ritonavir 100 mg once daily) in HIV-infected patients
Famotidin 20 mg dvaput na dan (atazanavir 300 mg/ritonavir 100 mg jedanput na dan) u bolesnika s HIV infekcijom
The peak concentration of digoxin is increased when co-administered with cobicistat.
Vršna koncentracija digoksina raste pri istodobnoj primjeni s kobicistatom.
Increased plasma concentrations of medicinal products that are metabolised by CYP3A, CYP2C8, CYP2D6 and/or UGT1A1 are expected when co-administered with EVOTAZ.
Pri istodobnoj primjeni s lijekom EVOTAZ očekuju se povišene plazmatske koncentracije lijekova koji se metaboliziraju putem CYP3A, CYP2C8, CYP2D6 i/ili UGT1A1.
Each single agent produced effects on left ventricular contractility and PR prolongation at concentrations at least 35-fold higher than the free atazanavir and cobicistat concentrations at the recommended human dose (RHD) Cmax.
Svaki je lijek zasebno utjecao na kontraktilnost lijeve klijetke i produljenje PR-intervala pri koncentracijama koje su bile najmanje 35 puta više od koncentracija slobodnog atazanavira i kobicistata pri vrijednosti Cmax koja se postiže nakon primjene preporučene doze za ljude.
Co-administration with the following medicinal products due to the potential for serious and/or lifethreatening adverse reactions (see section 4.5): colchicine, when used in patients with renal and/or hepatic impairment (antigout) (see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension (see sections 4.4 and 4.5 for co-administration for the treatment of erectile dysfunction), avanafil (PDE5 inhibitors) simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see section 4.5) grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) (see section 4.5) glecaprevir/pibrentasvir fixed dose combination (see section 4.5)
Istodobna primjena sa sljedećim lijekovima zbog mogućih ozbiljnih i/ili po život opasnih nuspojava (vidjeti dio 4.5): kolhicin, kada se koristi u bolesnika s oštećenjem bubrežne i/ili jetrene funkcije (lijek za liječenje gihta) (vidjeti dio 4.5) sildenafil - kada se koristi za liječenje plućne arterijske hipertenzije (vidjeti dijelove 4.4 i 4.5 za istodobnu primjenu kod liječenja erektilne disfunkcije), avanafil (inhibitori PDE-5) simvastatin i lovastatin (inhibitori HMG-CoA reduktaze) (vidjeti dio 4.5)
Atazanavir with cobicistat
Atazanavir s kobicistatom
Atazanavir, a component of EVOTAZ is excreted in human milk.
Atazanavir, sastojak lijeka EVOTAZ izlučuje se u majčino mlijeko.
Cobicistat is a strong mechanism-based CYP3A inhibitor and a weak CYP2D6 inhibitor.
Kobicistat je snažan inhibitor CYP3A temeljeno na mehanizmu i slab inhibitor CYP2D6.
Each film-coated tablet contains 300 mg of atazanavir (as sulphate), and 150 mg cobicistat.
Jedna filmom obložena tableta sadrži 300 mg atazanavira (u obliku atazanavirsulfata) i 150 mg kobicistata.
Voriconazole should not be co-administered with EVOTAZ unless the benefit/risk assessment justifies the use of voriconazole (see section 4.4).
Vorikonazol se ne smije primjenjivati istodobno s lijekom EVOTAZ, osim u slučajevima kada ocjena koristi/rizika opravdava primjenu vorikonazola (vidjeti dio 4.4).
There was an increase in the maximum PR interval compared to atazanavir alone.
Primijećeno je produljenje maksimalnog PRintervala u usporedbi s atazanavirom primijenjenim samostalno.
Co-administration of EVOTAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with the increase in grazoprevir concentrations (see section 4.3 and Table 1).
Istodobna primjena lijeka EVOTAZ s lijekovima koji sadrže grazoprevir, uključujući fiksnu kombinaciju elbasvir/grazoprevir (koja se koristi u liječenju kronične infekcije virusom hepatitisa C), kontraindicirana je zbog povišene koncentracije grazoprevira i elbasvira u plazmi, te postoji povećan rizik povišenja vrijednosti ALT-a zbog povišene koncentracije grazoprevira (vidjeti dio 4.3 i Tablicu 1).
There are no pharmacokinetic data available for atazanavir in combination with cobicistat in patients with renal insufficiency.
Nema dostupnih farmakokinetičkih podataka o primjeni atazanavira u kombinaciji s kobicistatom u bolesnika s insuficijencijom bubrega.
No clinically relevant pharmacokinetic differences due to gender have been identified for atazanavir or cobicistat.
Nisu identificirane klinički značajne farmakokinetičke razlike uvjetovane spolom koje bi bile povezane s atazanavirom ili kobicistatom.
Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may decrease the clearance of atazanavir and cobicistat, resulting in increased atazanavir and cobicistat plasma concentrations (see section 4.5).
Istodobna primjena lijeka EVOTAZ s lijekovima koji inhibiraju CYP3A može smanjiti klirens atazanavira i kobicistata, što za posljedicu može imati povišene plazmatske koncentracije atazanavira i kobicistata (vidjeti dio 4.5).
The demographic and baseline characteristics were similar between the atazanavir with cobicistat and atazanavir with ritonavir groups.
Demografske i početne značajke bile su slične u skupini liječenoj atazanavirom i kobicistatom i onoj liječenoj atazanavirom i ritonavirom.
Atazanavir is metabolised principally by CYP3A4.
Atazanavir se prvenstveno metabolizira putem CYP3A4.
Sofosbuvir 400 mg/velpatasvir, 100 mg/voxilaprevir 100 mg single dose* (atazanavir 300 mg with ritonavir 100 mg once daily)
Sofosbuvir 400 mg/velpatasvir, 100 mg/voksilaprevir 100 mg u jednokratnoj dozi* (atazanavir 300 mg s ritonavirom 100 mg jednom dnevno)
These medicinal products include alfuzosin, amiodarone, astemizole, bepridil, cisapride, colchicine, dronedarone, ergot deriviatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine), lovastatin, orally administered midazolam, pimozide, quetiapine, quinidine, lurasidone, simvastatin, sildenafil (when used to treat pulmonary arterial hypertension), avanafil, systemic lidocaine, ticagrelor, terfenadine and triazolam.
Među njih se ubrajaju alfuzosin, amiodaron, astemizol, bepridil, cisaprid, kolhicin, dronedaron, derivati ergota (npr. dihidroergotamin, ergometrin, ergotamin, metilergonovin), lovastatin, peroralno primijenjen midazolam, pimozid, kvetiapin, kinidin, lurasidon, simvastatin, sildenafil (kada se koristi za liječenje plućne arterijske hipertenzije), avanafil, sistemski lidokain, tikagrelor, terfenadin i triazolam.
Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated.
U bolesnika koji ne podnose dozu od 150 mg triput tjedno preporučuje se daljnje smanjenje doze rifabutina na 150 mg dvaput tjedno u određene dane.
If drospirenone/ethinyloestradiol is co-administered with atazanavir/cobicistat clinical monitoring is recommended due to the potential for hyperkalemia.
Ako se drospirenon/etinilestradiol primjeni istodobno s atazanavir/kobicistatom preporučuje se kliničko praćenje zbog moguće hiperkalemije.